- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07859722
CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
A Randomized Pragmatic Study of CT- Versus MRI-Based Planning for High-Dose-Rate Prostate Brachytherapy for Prostate Cancer
This clinical trial studies the safety of a computed tomography (CT) scan, with or without a magnetic resonance imaging (MRI) scan, in planning for high-dose-rate (HDR) prostate brachytherapy treatment in patients with prostate cancer. Brachytherapy is a type of radiation therapy in which radioactive implants, such as pellets, seeds, ribbons, wires, needles, balloons, or capsules, are placed in the body, directly into or near the tumor. The radiation is delivered through a flexible tube called a catheter or a larger device called an applicator. Treatment planning, or simulation, is a process used to plan radiation therapy so that the target area is precisely located and marked. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. An MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. The addition of MRI to CT for HDR prostate brachytherapy treatment planning may help patients have less urine leakage and less pain after treatment.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVE:
I. To compare acute changes in patient reported outcomes of urinary toxicity utilizing the Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
SECONDARY OBJECTIVES:
I. To compare acute and chronic changes in patient reported outcomes of toxicity utilizing the EPIC-26 Urinary Irritative/Obstructive, Bowel, and Sexual domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
II. To compare the cumulative incidence of physician reported Common Terminology Criteria for Adverse Events (CTCAE) acute and chronic grade 2+ genitourinary (GU) or gastrointestinal (GI) toxicity for patients undergoing prostate HDR brachytherapy planned with utilization of an MRI versus no MRI.
TERTIARY/EXPLORATORY OBJECTIVE:
I. To compare treatment efficacy for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo treatment planning with a CT scan for HDR brachytherapy.
ARM B: Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.
After completion of study intervention, patients are followed up at 1, 3, 6, and 12 months.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Sagar Patel, MD
- Número de teléfono: 404-778-1900
- Correo electrónico: sagar.patel@emory.edu
Copia de seguridad de contactos de estudio
- Nombre: Kamran Salari, MD
- Número de teléfono: 404-686-2391
- Correo electrónico: kamran.salari@emory.edu
Ubicaciones de estudio
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Reclutamiento
- Emory University Hospital/Winship Cancer Institute
-
Contacto:
- Ardith Deshay
- Número de teléfono: 404-251-0743
- Correo electrónico: ardith.deshay.deshay@emory.edu
-
Investigador principal:
- Kamran Salari, MD
-
Atlanta, Georgia, Estados Unidos, 30308
- Reclutamiento
- Emory University Hospital Midtown
-
Contacto:
- Ardith Deshay
- Número de teléfono: 404-251-0743
- Correo electrónico: ardith.deshay.deshay@emory.edu
-
Investigador principal:
- Kamran Salari, MD
-
Atlanta, Georgia, Estados Unidos, 30308
- Reclutamiento
- Emory Proton Therapy Center
-
Contacto:
- Ardith DeShay
- Número de teléfono: 404-251-0743
- Correo electrónico: ardith.deshay.deshay@emory.edu
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Men ≥ 18 years old
- Histopathologically confirmed prostate cancer
- No evidence of regional or distant metastases
- Plan to undergo curative-intent HDR brachytherapy with or without external beam radiation therapy
Exclusion Criteria:
- Prior pelvic radiation therapy
- No prior prostate MRI
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm A (CT, SOC HDR brachytherapy)
Patients undergo treatment planning with a CT scan for HDR brachytherapy. |
Ancillary studies |
|
Experimental: Arm B (CT, MRI, SOC HDR brachytherapy)
Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy. |
Ancillary studies Undergo MRI scan
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
Periodo de tiempo: At 1 month following treatment
|
The primary analysis will be conducted using a mixed-effects model for repeated measures (MMRM) including fixed effects for treatment arm, categorical time, treatment-by-time interaction, baseline Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence score, age, comorbidity status, and the stratification factors of high-dose-rate treatment approach and rectal spacer use. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. The primary treatment comparison will be the adjusted between-group difference at the 1-month time point derived from the treatment-by-time interaction using least-squares means, with corresponding two-sided 95% confidence intervals and p-values evaluated at a significance level of 0.05. |
At 1 month following treatment
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
Periodo de tiempo: At 3, 6 and 12 months following treatment
|
Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. |
At 3, 6 and 12 months following treatment
|
|
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Irritative/Obstructive, Bowel, and Sexual domain scores
Periodo de tiempo: At 1, 3, 6 and 12 months following treatment
|
Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary irritative/obstructive, bowel, and sexual domain scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. |
At 1, 3, 6 and 12 months following treatment
|
|
Cumulative incidence of grade 2 or higher genitourinary or gastrointestinal adverse events
Periodo de tiempo: Within 12 months following treatment
|
Will be analyzed using competing-risk methods to account for death as a competing event. Cumulative incidence functions will be estimated for each treatment arm and compared using Gray's test. Fine-Gray subdistribution hazard models, including stratification factors and relevant covariates, will be used to estimate adjusted hazard ratios with 95% confidence intervals. Adverse events will be coded using the Medical Dictionary for Regulatory Activities and graded according to Common Terminology Criteria for Adverse Events version 5.0. Safety analyses will summarize the frequency, severity, and relationship of adverse events to study treatment by System Organ Class and preferred term. Each adverse event will be counted once per participant at the maximum severity grade. Serious adverse events and events leading to treatment discontinuation will be summarized separately. |
Within 12 months following treatment
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kamran Salari, MD, Emory University Hospital/Winship Cancer Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Neoplasias prostáticas
- Técnicas de investigación
- Técnicas de química, analítica
- Análisis de espectro
- Espectroscopía de resonancia magnética
Otros números de identificación del estudio
- 2026P000571
- P30CA138292 (Subvención/contrato del NIH de EE. UU.)
- NCI-2026-06309 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- 2026P000571 (Otro identificador: Emory University Hospital/Winship Cancer Institute)
- RAD6975-26 (Otro identificador: Emory University Hospital/Winship Cancer Institute)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .